Search Clinical Trials in the European Union

Duration
Visits
Phase
Injection
Benefits
Drugs
Locations
Clinical Specialty
981-1000 of 2,120 trials

Rheumatoid Arthritis: FBL-MTX Injection Study

We are investigating a new injectable treatment for moderate-to-severe rheumatoid arthritis in patients who haven't used DMARDs or have had issues with oral methotrexate. The study will evaluate how well it works and its safety.

Rheumatoid Arthritis3-6 monthsEfficacy phase (II)6-10 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesInternal MedicineRheumatology

Solid Tumors: E7386 with Other Anticancer Drugs

We are studying the safety and effectiveness of E7386 combined with other anticancer treatments for patients with solid tumors. This trial aims to find the best dose and assess how well it works compared to standard therapies.

Liver Cancer (Hepatocellular Carcinoma)Colorectal CancerEndometrial CancerSafety phase (I)Efficacy phase (II)No PlaceboInvestigational MedicinesPartially RemoteOncology

Prurigo Nodularis: Barzolvolimab Study

We are testing a new medication, barzolvolimab, for people with prurigo nodularis to see if it helps reduce itching and improve skin lesions. The study will also look at the safety of this treatment and its effects on quality of life.

Prurigo Nodularis6-12 monthsEfficacy phase (II)6-10 visitsPost-Trial Drug AccessInvestigational MedicinesAllergologyDermatology

Chronic Graft-Versus-Host Disease: Axatilimab Treatment

We are studying whether axatilimab, combined with corticosteroids, helps improve symptoms in patients with moderate to severe chronic graft-versus-host disease. This trial compares its effects to a placebo.

Chronic Graft-Versus-Host DiseaseConfirmation phase (III)>20 visitsPost-Trial Drug AccessInvestigational MedicinesCost ReimbursementHematologyInfectious Diseases

Chronic Lymphocytic Leukemia: Venetoclax and Pirtobrutinib Study

We are comparing different treatment plans for newly diagnosed chronic lymphocytic leukemia patients to see if a personalized approach improves outcomes. This includes assessing how long patients can stay in remission and the overall effectiveness of the treatments.

Chronic Lymphocytic Leukaemia (CLL)Small Lymphocytic Lymphoma (SLL)>2 yearsConfirmation phase (III)11-15 visitsNo PlaceboStandard MedicinesPartially RemoteHematologyOncology

Chronic Inflammatory Diseases: Low-Dose Interleukin-2 Therapy

We are studying the safety and effectiveness of low-dose interleukin-2 therapy for patients with conditions like Pemphigus vulgaris and Mucous Membrane Pemphigoid. This trial aims to see how well this treatment works compared to a placebo.

Primary Sclerosing Cholangitis (PSC)Mucous Membrane PemphigoidPolymyositis/Dermatomyositis3-6 monthsEfficacy phase (II)≤5 visitsNo PlaceboStandard MedicinesCost ReimbursementDermatologyInfectious DiseasesRheumatology

Pamidronate for Pain in Sternocostoclavicular Hyperostosis

We are studying whether pamidronate can help reduce pain in patients with sternocostoclavicular hyperostosis. This trial will also look at improvements in daily activities and overall health.

Inflammation of the Sternal RegionSternocostoclavicular Hyperostosis1-2 yearsConfirmation phase (III)≤5 visitsPost-Trial Drug AccessStandard MedicinesOrthopedics and TraumatologyRheumatology

Head and Neck Cancer: Petosemtamab Treatment Study

We are studying the effects of petosemtamab in patients with advanced head and neck cancer who have not responded to previous treatments. The goal is to see if it improves survival and tumor response compared to standard therapies.

Metastatic Head and Neck Squamous Cell Carcinoma>2 yearsConfirmation phase (III)11-15 visitsNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteOncology

Head and Neck Cancer: Petosemtamab with Pembrolizumab

We are studying a new treatment combination for patients with recurrent or metastatic head and neck cancer to see if it works better than standard treatment. This trial is for those with tumors that express PD-L1.

Metastatic Squamous Cell Carcinoma of the Head and Neck>2 yearsConfirmation phase (III)No PlaceboStandard MedicinesPartially RemoteOncology

Uveal Melanoma: Tebentafusp Treatment Study

We are studying whether the drug tebentafusp can help prevent cancer recurrence in patients with high-risk uveal melanoma after surgery or radiation. This trial also looks at the safety of the treatment compared to observation.

Uveal Melanoma6-12 monthsConfirmation phase (III)No PlaceboStandard MedicinesOncologyOphthalmology

Paroxysmal Nocturnal Hemoglobinuria: Pozelimab and Cemdisiran Therapy

We are studying the long-term safety and effectiveness of a combination therapy for adults with Paroxysmal Nocturnal Hemoglobinuria. This trial will help us understand its impact on symptoms like fatigue and hemoglobin levels.

Paroxysmal Nocturnal Hemoglobinuria>2 yearsConfirmation phase (III)11-15 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteHematologyInternal Medicine

Hypereosinophilic Syndrome: Depemokimab Study

We are investigating whether Depemokimab can help adults with Hypereosinophilic Syndrome manage their symptoms better than a placebo. This study aims to provide insights into its effectiveness and safety.

Hypereosinophilic Syndrome1-2 yearsConfirmation phase (III)Post-Trial Drug AccessInvestigational MedicinesCost ReimbursementPartially RemoteHematologyInternal Medicine

Myotonic Dystrophy Type 1: DYNE-101 Treatment Study

We are evaluating the safety and effects of a new treatment, DYNE-101, for people with Myotonic Dystrophy Type 1. The study aims to see how it impacts muscle health and overall well-being.

Myotonic Dystrophy>2 yearsSafety phase (I)Efficacy phase (II)16-20 visitsPost-Trial Drug AccessInvestigational MedicinesPartially RemoteNeurologyOrthopedics and Traumatology

Pneumococcal Vaccine Response: Age and HIV Impact

We are studying how age and HIV infection affect the immune response to pneumococcal vaccination. This research aims to improve vaccine effectiveness for different populations.

HIV Infection6-12 monthsConfirmation phase (III)Monitoring phase (IV)6-10 visitsNo PlaceboStandard MedicinesCost ReimbursementInfectious DiseasesInternal Medicine

Mixed Dyslipidemia: RBD5044 Treatment Study

We are testing a new medication, RBD5044, for people with mixed dyslipidemia to see if it improves cholesterol and lipid levels. The study also looks at the safety of this treatment when given as injections.

Mixed Dyslipidemia6-12 monthsEfficacy phase (II)≤5 visitsInvestigational MedicinesCardiologyInternal Medicine

Cystic Fibrosis: Anakinra Treatment Study

We are testing the safety and effectiveness of anakinra for adults and possibly adolescents with cystic fibrosis. The study aims to see if it improves lung function and quality of life.

Cystic Fibrosis>2 yearsEfficacy phase (II)Standard MedicinesInternal MedicinePulmonology

Severe Diffuse Cutaneous Systemic Sclerosis: Rapcabtagene Autoleucel vs. Rituximab

We are studying a new treatment to see if it works better than rituximab for people with severe diffuse cutaneous systemic sclerosis. The trial will also evaluate the safety of this new therapy.

Systemic Scleroderma1-2 yearsEfficacy phase (II)6-10 visitsNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteInternal MedicineRheumatology

Multiple Myeloma: Teclistamab with Lenalidomide

We are studying a new treatment combining teclistamab and lenalidomide for patients with newly diagnosed multiple myeloma after stem cell transplant. The aim is to see if this combination works better than lenalidomide alone in maintaining remission.

Newly Diagnosed Multiple MyelomaConfirmation phase (III)Post-Trial Drug AccessNo PlaceboStandard MedicinesCost ReimbursementPartially RemoteHematologyOncology

Cirrhosis Treatment: Pegozafermin Study

We are studying a new medication, pegozafermin, for individuals with compensated cirrhosis due to MASH. The goal is to see if it can improve liver health and reduce related health risks compared to a placebo.

Chronic Liver Disease and Cirrhosis>2 yearsConfirmation phase (III)11-15 visitsPost-Trial Drug AccessInvestigational MedicinesCost ReimbursementPartially RemoteEndocrinologyHepatology

Postoperative Sleep Quality: DEXSLEEP Study

We are testing whether dexmedetomidine can improve sleep and reduce fatigue in elderly patients after major surgery. This may help enhance recovery and overall well-being following surgery.

Healthy Participants Aged 60 and Older1-2 yearsMonitoring phase (IV)No PlaceboStandard MedicinesInternal MedicineOtolaryngologyPsychiatry